Date & Time of Session - 4/1/26 - from 2:30 - 3:30PM

Overview
The National Comprehensive Cancer Network has recently created a new guideline, entitled “NCCN Guidelines for Management of CAR T-cell and Lymphocyte Engager-Related Toxicities”, signaling a stronger consensus on how to treat the toxicities associated with these novel therapy options. Both inpatient and outpatient pharmacists are likely to treat patients receiving these therapies and should be aware of toxicity management strategies, especially as new medications and indications continue to be approved. This presentation will provide an overview of CAR-T and BiTE therapies, discuss their key toxicities, and evaluate current literature and guidelines on the management of CRS and ICANS.

Objectives
Upon completion of this activity, the participant will be able to:
1. Describe the evolving role of chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (BiTE) therapies in hematology and oncology.
2. Review key adverse events associated with CAR-T and BiTE therapies.
3. Evaluate current literature and guidelines surrounding treatment of cytokine release syndrome (CRS) and immune-effector cell-associated neurotoxicity syndrome (ICANS). 
4. Design treatment regimens for patients with CRS and ICANS.

Target Audience
Pharmacists, physicians, nurses, fellows and residents

Speaker
CJ Sadler, PharmD
PGY2 Hematology/Oncology Pharmacy Resident 
Norton Children’s Hospital - Louisville, Kentucky